| Balance Sheet Components |
Balance Sheet Components Inventory Inventory consists of the following (in thousands): | | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | Raw materials | $ | 2,790 | | | $ | 2,998 | | | Work in progress | 14,258 | | | 9,873 | | | Finished goods | 4,546 | | | 9,441 | | | Total inventory | $ | 21,594 | | | $ | 22,312 | |
Accrued Expenses Accrued expenses consist of the following (in thousands): | | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | Accrued sales deductions | $ | 40,591 | | | $ | 23,650 | | | Accrued compensation and related benefits | 23,077 | | | 20,939 | | | Accrued professional service fees | 11,851 | | | 7,941 | | | Accrued contract manufacturing and non-clinical costs | 8,560 | | | 9,922 | | | Accrued royalties payable | 8,637 | | | 6,716 | | | Accrued clinical trials | 6,713 | | | 7,268 | | | Accrued interest | 5,271 | | | 2,108 | | | Total accrued expenses | $ | 104,700 | | | $ | 78,544 | |
|